Wednesday, April 19, 2017 12:04:03 PM
Answer: The vaccine we have developed has the potential to be beneficial in multiple stages of breast cancer. The most recent grant funding we received deals with the administration of this vaccine to individuals with DCIS. Although DCIS is not cancer, about 30% to 40% of individuals with DCIS will go on to develop cancer, but we typically do not know which patients with DCIS will develop cancer. These patients often are treated with surgery and endocrine therapy, and sometimes radiation therapy. Because the majority of individuals will not be diagnosed with cancer, there is a need to come up with a way to treat DCIS without the surgery, hormonal therapy and radiation therapy. Our thought — which has been observed with early cervical lesions — is that if we stimulate the immune system, the vaccine can potentially eliminate the early cancer-like lesion so that it goes away. The idea is this vaccine ultimately will protect against progression to cancer.
Q: What is included in the vaccine?
A: These are special types of vaccines. They are based upon antigens that are not microbial, so they are not virally derived. They are actually antigens that are coded by human genes that just so happen to be upregulated in cancer, and the immune system is able to recognize it.
Q: What will the study entail?
A: In our initial set of vaccine studies, we have found that we need about 6 months to immunize the individual against these antigens that are overexpressed by the cancer. The trial design we have is unique because we want to give the vaccine to patients before they are treated for DCIS. The question we will be asking is whether the vaccine eliminates the DCIS. However, we cannot do this over the course of 6 months, because standard care for DCIS is surgical removal, and 6 months is a long time to wait between diagnosis and surgery. We have to come up with an accelerated way to do this. In this trial, women diagnosed with DCIS will receive a course of four vaccinations — given every 2 weeks — followed by standard surgical resection. We additionally need to determine if the trial design needs to be a dose–response trial design in which we will escalate the dose in these individuals. We will have different groups of individuals on different doses with the purpose of generating immunity faster than we have seen achieved in past clinical trials. Once we identify the appropriate dose in these patients, we can add more individuals to the dose we find optimal.
Q: What do you expect to find?
A: This is an early-phase clinical trial. We expect to find that we can safely generate an immune response in individuals who do not have cancer. This is very important, because this is a group of individuals who are at low risk for developing cancer, and we are asking to generate an immune response against a protein that is normally found in the body. One of the central questions is whether the vaccine is safe. We have preliminary data from another 22 patients that the vaccine will be safe. We hypothesize that we will be able to safely generate an immune response. We will be looking at these primary outcomes. Secondarily, we will be looking at whether we can induce immune responses to migrate into the breast, where the precancerous lesion is, and then address whether that immune response is able to shrink or eliminate the cancer.
Q: If this trial is successful, in what type of setting will the vaccine be offered to patients?
A: There are a number of different settings. Women are essentially monitored on a regular basis using mammograms, which are primarily responsible for finding these lesions. I would anticipate that — if this vaccine is successful and a vaccine is produced — patients who have a mammographic finding will have a choice to take the vaccine with the hope that it will protect against the cancer in the future, or they can receive standard therapy with surgery, followed by hormone therapy and radiation therapy. I would assume that, if the vaccine does work, most people would choose this over surgery and radiation therapy.
Q: What is the potential for a vaccine like this to protect against other cancer types?
A: The potential exists for this vaccine to protect against other cancer types. The molecule that we are targeting in this particular case is HER2/neu, which has been a target for breast cancer in the past. A number of other cancers also express HER2/neu and, because of this, there could be the potential for protecting against other cancer types. However, the only way to rigorously test against this is through clinical trial.
Q: What will future research entail?
A: This clinical trial will enroll between 40 and 45 patients. This will give us important information about whether the vaccine will work. There are a number of things that need to occur before additional studies will be generated. The vaccine needs to be safe. It also has to generate an immune response, and that immune response has to have an impact on the cancer. Once we see this, which we hope we will, we can then design a more advanced clinical trial to see if this has any impact on the disease. In this particular case, some women would have to be on placebo and other women would receive the vaccine so that we know if women who received the vaccine had better outcomes than women who did not receive the vaccine.
Q: Is there anything else that you would like to mention?
A: We ultimately want to prevent the development of cancer, and we think that we can do this by stimulating the body’s immune system. The approaches we are using are more therapeutic than standard preventive vaccines like the flu vaccine, for example. We think the research we are doing now ultimately will lead to the development of a prevention vaccine that we can give to women in their 40s, for example, and prevent a sizable portion of breast cancer cases from occurring.
Recent MRKR News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 11:22:44 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM